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The time interval between kidney and
pancreas transplantation and the clinical
outcomes of pancreas after kidney
transplantation
Pancreas after kidney (PAK) transplantation is one
of the accepted pancreas transplant modalities (1,
2). PAK transplantation allows uremic type 1
diabetic patients to receive a life-saving kidney
transplant first and then a subsequent pancreas
transplant to correct hyperglycemia (3). Histori-
cally, PAK transplants have a lower pancreas graft
survival rate compared with simultaneous pancreas
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Abstract: Pancreas after kidney (PAK) transplantation is one of the
accepted pancreas transplant modalities. We studied the impact of time
interval between kidney and pancreas transplantation on the outcomes of
PAK transplantation. Using OPTN/SRTR data, we included 1853 PAK
transplants performed between 1996 and 2005 with follow-up until
November 1, 2008. Kaplan–Meier survival and multivariate Cox regression
analyses were performed using the time interval between kidney and pan-
creas transplantation either as a categorical (less than one yr, between one
and less than three yr, and greater than or equal to three yr) or as a
continuous variable (months) to assess kidney graft and patient survival.
Patients who received a pancreas transplant three yr or later after kidney
transplantation had higher risk of death-censored kidney graft loss (HR
1.56, 95% CI 1.04, 2.32, p = 0.03). Each month beyond three yr between
kidney and pancreas transplantation incurred 1% higher risk of subsequent
death-censored kidney graft loss (HR 1.01, 95% CI 1.001, 1.02, p = 0.03).
In conclusion, time interval between pancreas and kidney transplantation is
an independent risk factor of kidney graft loss following pancreas trans-
plantation. Shortening the time interval between pancreas and kidney
transplantation to less than three yr may reduce the risk of kidney graft loss
in qualified PAK transplant candidates.
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and kidney transplants although lately some single-
center studies have reported comparable results
(3–5). Furthermore, one study has suggested that
PAK transplant recipients had inferior patient
survival compared with wait-listed PAK candi-
dates treated with conventional insulin therapy (6).
Several investigators over the years have exam-
ined the potential risk factors associated with poor
PAK outcome, including the timing elapsed
between pancreas and kidney transplantation (7,
8). The number of patients included in these studies
was limited. One recent study, however, did show
that timing of pancreas transplantation has an
impact on the clinical outcome as the time interval
between kidney and pancreas transplantation long-
er than one yr was associated with inferior uncen-
sored kidney graft survival post-pancreas
transplantation (8).
We hypothesized that the longer time interval
between kidney and pancreas transplantation
could predispose kidney transplant to the develop-
ment of chronic injuries, immunologic or not, and
thus negatively impact kidney graft and/or patient
survival after pancreas transplantation. We under-
took a retrospective analysis of national registry
data to determine the effect of time interval on
pancreas and kidney graft survival and mortality
risk among PAK transplant patients.
Materials and methods
We included all adult primary PAK transplants
performed between January 1, 1996 and December
31, 2005 in the United States with follow-up until
November 1, 2008. Data were collected and
provided by the Organ Procurement and Trans-
plantation Network (OPTN)/Scientific Registry of
Transplant Recipients (SRTR). The SRTR data
system includes data on all donors, wait-listed
candidates, and transplant recipients in the United
States, submitted by the members of the OPTN,
and has been described elsewhere (9). The Health
Resources and Services Administration (HRSA),
US Department of Health and Human Services,
provides oversight to the activities of the OPTN
and SRTR contractors. The study was approved
by the Institutional Review Board (IRB).
We identified the date of kidney and pancreas
transplantation and calculated the time interval
elapsed between kidney and pancreas transplan-
tation. This time interval was then utilized either
as a categorical variable separating all PAK
transplant recipients into three groups (less than
one yr, one to less than three yr, and greater than
or equal to three yr) or as a continuous variable
(months) and incorporated into multivariate
analyses separately. As Group 3 included a larger
proportion of kidney transplant patients from
1995 or earlier, to account for the possible
influence of era in transplant care, we created
era 1995 or earlier and era after 1995 as an
indicator variable. This era covariate was incor-
porated into all multivariate analyses. In addition,
baseline recipient- and donor-related characteris-
tics were examined and used in multivariate
analyses as well. Other important variables con-
sidered in the multivariate analyses included the
baseline renal allograft function post-kidney
transplant and at the time of pancreas transplan-
tation, expressed as estimated glomerular filtration
rate (eGFR) and calculated using the abbreviated
Modification of Diet in Renal Disease (aMDRD)
prediction equation, surgical modality in exocrine
pancreas drainage (bladder vs. enteric), the use of
various immunosuppressive agents at the time of
kidney and pancreas transplantation, induction
and maintenance, and center volume of pancreas
transplants performed at a given year.
Demographic and baseline characteristics from
the time of pancreas transplantation were com-
pared using ANOVA and chi-square test among
the three groups of PAK patients. The time at risk
of the outcomes of interest, death and death-
censored kidney graft loss, started at the time of
pancreas transplantation as both outcomes could
not happen prior to pancreas transplantation by
the nature of study design. Kaplan–Meier survival
analyses were carried out for composite event-free
survival, for death-censored pancreas and kidney
transplants survival, and patient survival. Several
sets of multivariate Cox proportional hazards
regression models using a backward selection
approach were performed to assess the effects of
time interval and to identify other independent risk
factors on death-censored pancreas and kidney
graft loss and death. Analyses were performed
using SAS 9.1, (Cary, NC, USA) and statistical
significance was set at p £ 0.05.
Results
We identified a total of 1853 PAK transplant
recipients during the study period with complete
information on the date of both organ transplants
and clinical follow-up. The mean and median time
between kidney and pancreas transplant was 31.7
(±35.8) and 17.1 (0.1, 200.7) months, respectively.
The mean age was 41.5 (±7.6) yr. African Amer-
ican patients accounted for 7.3% of PAK patients.
The majority of kidney transplants were from a
living donor (70.9%). The mean eGFR at the time
of pancreas transplant was 60.4 (±17.8) mL/min.
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PAK transplant recipients were separated into
three groups according to the time interval between
kidney and pancreas transplantation: Group 1 with
less than one yr, Group 2 from one to less than
three yr, and Group 3 with three or more years
between the two transplant events. PAK transplant
recipients from the three groups differed in several
demographic and baseline characteristics (Table 1).
PAK transplant recipients fromGroup 3 were older
(42.9 yr vs. 40.9 and 41.1 yr in Group 1 and 2,
respectively, p < 0.001) and had shorter duration
of diabetes at kidney transplant (24.8 yr vs. 26.2 and
25.0 yr in Group 1 and 2, respectively, p = 0.002).
They received less often a preemptive kidney
transplant (16.3% vs. 32.1% and 26.7% in Group
1 and 2, respectively, p < 0.001) and had fewer
living donor kidney transplants (60.6% vs. 77.3%
and 72.3% in Group 1 and 2, respectively,
p < 0.001), although the kidney donor age was
younger for Group 3 PAK transplant recipients
(34.9 yr vs. 40.1 and 38.5 yr in Group 1 and 2,
respectively, p < 0.001). Bladder drainage of pan-
creas transplant was more frequently utilized
among patients from Group 3 (48.4% vs. 38.3%
and 30.4% in Group 1 and 2, respectively,
p < 0.001). There were also significant differences
in immunosuppression regimens at the time of
kidney transplantation as PAK transplant recipi-
ents from Group 3 often received no induction
(71.8% vs. 44.5% and 49.7% in Group 1 and 2,
respectively, p < 0.001), more frequently used
cyclosporine (81.7% vs. 36.1% and 47.2% inGroup
1 and 2, respectively, p < 0.001) and less frequently
mycophenolates (32.2% vs. 73.7% and 73.3% in
Group 1 and 2, respectively, p < 0.001). However,
at the time of pancreas transplantation, the differ-
ence in immunosuppression regimens was much less
striking (Table 1). While baseline renal function
post-kidney transplant was comparable, the renal
function at the time of pancreas transplantation was
significantly lower for PAK transplant recipients in
Group 3 (57.2 vs. 61.4 and 61.6 mL/min in Group 1
and 2, respectively, p < 0.001).
Following pancreas transplantation, PAK trans-
plant recipients from Group 3 displayed overall
inferior clinical outcome (Fig. 1A, log-rank
p = 0.01). This was mainly related to reduced
death-censored kidney graft survival as well as
patient survival (Fig. 1B and C, log-rank
p < 0.0001 and p < 0.001, respectively). Pancreas
allograft survival, early (within 90 d) and during
subsequent years, was not different between the
three groups (data not shown). Multivariate Cox
proportional hazards regression analyses demon-
strated that the time interval equal to or greater
than three yr between kidney and pancreas
transplantation was independently and signifi-
cantly associated with increased risk of death-
censored kidney graft loss (HR 1.56, 95% CI 1.04,
2.32, p = 0.03 with era as a covariate) (Table 2).
This was further confirmed in an alternate analysis
using the time interval between kidney and pan-
creas transplantation as a continuous variable.
Each month beyond three yr between kidney and
pancreas transplantation incurred 1% increase in
the risk of kidney graft loss (HR 1.01, 95% CI
1.001, 1.02, p = 0.03). As an alternative analytic
approach, we performed a different set of multi-
variate Cox proportional hazards regression
analyses using pancreas transplantation as a time-
dependent covariate and with starting point at the
time of kidney transplantation, and we found an
even greater increase in the risk associated with
longer time interval (HR 1.66, 95% CI 1.18, 2.35,
p = 0.004 for time interval between one and less
than three yr and HR 2.27, 95% CI 1.54, 3.33,
p < 0.001 for time interval greater than or equal
to three yr, respectively) although we felt that a
greater bias was created because of inclusion of all
patients prior to pancreas transplantation in the
reference group as they were not at risk for the
study outcomes (death and kidney graft loss) until
after their pancreas transplantation. Other factors
contributing to the risk of kidney graft loss
following pancreas transplantation included older
kidney donor age (HR 1.01, 95% CI 1.003, 1.03,
p = 0.011), the use of kidneys from expanded
criteria donor (ECD) and/or donor after cardiac
death (DCD) (HR 2.38, 95% CI 1.63, 3.48,
p < 0.001), and the use of alemtuzumab as an
induction agent at the time of kidney transplanta-
tion (HR 3.11, 95% CI 1.24, 7.76, p = 0.015). On
the other hand, older recipient age and higher renal
function at the time of pancreas transplantation
were associated with reduced risk of subsequent
kidney graft loss (Table 2). The duration of diabe-
tes exposure up to the time of kidney transplanta-
tion did not appear to negatively impact kidney
graft survival post-pancreas transplantation. Fur-
thermore, the time interval between kidney and
pancreas transplantation did not appear to be
associated with increased risk of death when the
era effect was incorporated into the model
(Table 3). Other factors that negatively affected
patient survival included older recipient age at the
time of pancreas transplantation (HR 1.03, 95%
CI 1.01, 1.06, p = 0.002), previous dialysis history
(HR 1.74, 95% CI 1.30, 2.33, p < 0.001), history
of peripheral vascular disease (HR 1.58, 95% CI
1.17, 2.79, p = 0.003), history of coronary artery
disease (HR 1.51, 95% CI 1.16, 1.97, p = 0.002),
and African American kidney donor (HR 1.95,
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Table 1. Demographic and baseline characteristics of study patient population
Group 1 Group 2 Group 3
pN = 726 N = 592 N = 535
Age, yr (SD) 40.9 (7.9) 41.1 (7.8) 42.9 (6.9) <0.001
Gender: male (%) 416 (57.3) 354 (59.8) 308 (57.6) 0.622
Race: African American (%) 45 (6.2) 52 (8.8) 38 (7.1) 0.196
BMI, kg/m2 (SD) 24.9 (4.1) 25.5 (4.2) 25.1 (4.2) 0.017
Duration of diabetes at kidney transplant, yr (SD) 26.2 (7.9) 25.0 (7.9) 24.8 (6.5) 0.002
Dialysis history, yes (%) 493 (67.9) 434 (73.3) 448 (83.7) <0.001
Angina/coronary artery disease, yes (%) 129 (17.8) 103 (17.4) 81 (15.1) 0.433
History of blood transfusion, yes (%) 301 (41.5) 267 (45.1) 282 (52.7) <0.001
Peripheral vascular disease, yes (%) 60 (8.2) 66 (11.2) 65 (12.2) 0.058
Cerebrovascular disease, yes (%) 19 (2.6) 20 (3.4) 14 (2.6) 0.657
History of hypertension, yes (%) 574 (79.1) 465 (78.6) 379 (70.8) 0.001
Kidney donor type (%)
Living 561 (77.3) 428 (72.3) 324 (60.6) <0.001
SCD 142 (19.6) 136 (23.0) 139 (26.0)
ECD or DCD 23 (3.2) 28 (4.7) 72 (13.5)
Kidney donor age, yr (SD) 40.1 (12.5) 38.5 (12.6) 34.9 (13.5) <0.001
Pancreas donor age, yr (SD) 26.8 (10.9) 26.0 (10.4) 26.1 (11.1) 0.380
Kidney donor race: African American (%) 38 (5.2) 35 (5.9) 25 (4.7) 0.648
Kidney donor gender: male (%) 274 (46.3) 326 (44.9) 270 (50.5) 0.137
Era of kidney transplant: 1995 or earlier (%) 18 (2.5) 45 (7.6) 305 (57.0) <0.001
eGFR 6 months post-kidney transplant, mL/min (SD) 58.8 (19.0) 60.0 (17.9) 59.4 (17.5) 0.553
eGFR at pancreas transplantation, mL/min (SD) 61.4 (17.6) 61.6 (17.6) 57.2 (18.2) <0.001
HLA mismatches at kidney transplantation (SD) 2.78 (1.81) 2.66 (1.85) 2.42 (1.80) 0.003
HLA mismatches at pancreas transplantation (SD) 3.8 (1.4) 4.0 (1.3) 3.9 (1.5) 0.100
Peak PRA at pancreas transplantation (SD) 7.5 (18.0) 9.7 (21.2) 11.9 (23.0) 0.001
Bladder drainage of pancreas, yes (%) 278 (38.3) 180 (30.4) 359 (48.4) <0.001
CNIs at kidney transplantation (%)
None 38 (5.2) 30 (5.1) 14 (2.6) <0.001
Cyclosporine 262 (36.1) 279 (47.2) 437 (81.7)
Tacrolimus 426 (58.7) 283 (47.8) 84 (15.7)
Anti-metabolites at kidney transplantation (%)
None 57 (7.9) 43 (7.3) 54 (10.1) <0.001
Mycophenolates 535 (73.7) 434 (73.3) 172 (32.2)
Sirolimus/everolimus 70 (9.6) 42 (7.1) 22 (4.1)
Imuran and others 64 (8.8) 73 (12.3) 287 (53.6)
Steroids at kidney transplantation, yes (%) 678 (93.4) 577 (97.5) 528 (98.7) <0.001
Induction at kidney transplantation (%)
None 323 (44.5) 294 (49.7) 384 (71.8) <0.001
ATG/Thymoglobulin 228 (31.4) 129 (21.8) 95 (17.8)
Anti-IL2 receptor antibodies 151 (20.8) 161 (27.2) 56 (10.5)
Alemtuzumab 24 (3.3) 8 (1.4) 0 (0)
CNIs at pancreas transplantation (%)
None 64 (8.8) 60 (10.1) 40 (7.5) 0.046
Cyclosporine 75 (10.3) 89 (15.0) 70 (13.1)
Tacrolimus 587 (80.9) 443 (74.8) 425 (79.4)
Anti-metabolites at pancreas transplantation (%)
None 83 (11.4) 58 (9.8) 49 (9.2) 0.437
Mycophenolates 566 (78.0) 473 (79.9) 413 (77.2)
Sirolimus/everolimus 65 (9.0) 49 (8.3) 59 (11.0)
Imuran/others 12 (1.7) 12 (2.0) 14 (2.6)
Steroids at pancreas transplantation, yes (%) 674 (92.8) 562 (94.9) 506 (94.6) 0.226
Induction at pancreas transplantation (%)
None 193 (26.6) 152 (25.7) 134 (25.1) <0.001
ATG/thymoglobulin 382 (52.6) 298 (50.4) 277 (51.7)
Anti-IL2 receptor antibodies 83 (11.4) 104 (17.6) 100 (18.7)
Alemtuzumab 68 (9.4) 38 (6.4) 24 (4.5)
BMI, body mass index; HLA, human leukocyte antigens; PRA, panel reactive antibodies; SCD, standard criteria donor; ECD, expanded criteria donor; DCD, donor after
cardiac death; eGFR, estimated glomerular filtration rate; ATG, anti-thymocyte globulin.
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95% CI 1.29, 2.94, p = 0.001). Higher body mass
index and renal function at the time of pancreas
transplantation were associated with lower risk of
death (HR 0.95, 95% CI 0.93, 0.98, p = 0.001 and
HR 0.99, 95% CI 0.98, 0.994, p < 0.001, respec-
tively).
Although the changing in renal function over the
time, expressed as the slop, was not significantly
different among the three groups (0.24 ± 4.42,
0.18 ± 1.70, and )0.03 ± 0.39 for patients from
Groups 1, 2, and 3, respectively, p = 0.25), eGFR
at the time of pancreas transplantation was signif-
icantly lower for PAK patients from Group 3 and
was independently associated with post-pancreas
transplant outcomes. We further investigated the
impact of actual eGFR divided according to three
tertiles (Table 4). Patients in the highest tertile had
eGFR equal to or >65 mL/min, those in the mid-
tertile between 50 and <65 mL/min, and those in
the lowest tertile <50 mL/min. Using patients in
the highest tertile as a reference group, patients
with eGFR in the mid- and lower tertiles had 27%
and 93% higher risk of death-censored kidney
graft loss (p = 0.19 and p < 0.001, respectively).
Similarly, patients with eGFR in the mid- and
lower tertiles had 51% and 95% higher risk of
death (p = 0.005 and p < 0.001, respectively).
Discussion
This study demonstrates that the time interval
between kidney and pancreas transplantation inde-
pendently impacts the clinical outcome of PAK
transplantation, in particular, death-censored kid-
ney graft survival. There appears to be a threshold
effect, namely, a time interval equal to or greater
than three yr between the two transplant events
was associated with a significant increase in the risk
of death-censored kidney graft loss that was
independent of kidney function at the time of
pancreas transplantation. Speculation on possible
mechanisms for this negative effect of longer time
interval could involve the progressive development
of kidney graft injuries with the time, immunologic
or not such as subclinical acute rejection, calcineu-
rin inhibitor (CNI) nephrotoxicity, and continued
exposure to the diabetic environment, etc. (10–14).
On the other hand, the time interval did not appear
to negatively impact patient survival following
pancreas transplant when the effect of era in which
kidney transplantation was performed was taken
into consideration. In addition, renal function at
the time of pancreas transplantation played an
important role in determining the clinical outcome
of post-pancreas transplantation. These findings
should help the transplant community to provide
appropriate counseling for qualified type 1 diabetic
kidney transplant patients in pursue of pancreas
transplantation.
PAK transplantation is one of the pancreas
transplant modalities endorsed by the American
Diabetes Association for qualified patients with
diabetic end-stage renal disease (ESRD) who had a
successful kidney transplant (2). As the life-saving
property of a kidney transplant has been firmly
established (15), the major advantage of PAK
transplantation is to allow patients with type 1
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Fig. 1. Kaplan–Meier survival analyses among three groups of
pancreas after kidney transplant patients: (A) composite event-
free survival, (B) death-censored kidney graft survival and (C)
patient survival.
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diabetic ESRD to receive a living donor kidney
transplant as soon as this is available, while still
having the possibility of receiving a pancreas
transplant later on. This approach also has the
potential to increase both the deceased donor
kidney and pancreas pools (16). Notwithstanding
this benefit, one of the main concerns of this
approach is the potentially negative effect that
pancreas transplantation can have on the function
and the lifespan of previous kidney transplant (1, 6,
15). A few studies have addressed the question of
whether the time interval elapsed between the two
transplant procedures impacts the outcome of
PAK transplantation (7, 8). Chronic kidney allo-
graft injuries, in the form of interstitial fibrosis and
tubular atrophy, can be detected as early as within
the first year of kidney transplantation, either as a
result of undetected subclinical acute rejection or
CNI nephrotoxicity, and increase progressively
with time (10, 13, 14, 17). Furthermore, contin-
ued diabetes exposure following kidney transplan-
tation has also been shown to cause renal
transplant injuries (11, 12). In one study, PAK
transplant recipients who received a pancreas
transplant with a time interval between the two
transplant procedures greater than four months
had no difference in outcomes when compared with
those with a time interval less than four months
(7). On the other hand, one recent study involving
126 PAK transplant recipients reported that a time
interval greater than one yr between kidney and
Table 2. Clinical correlates of kidney graft loss following pancreas trans-
plantation
Variables Hazard ratio 95% CI p
Model 1a Years between
transplantations
0.07
<1 yr Ref. Ref. Ref.
1 to <3 yr 1.07 0.76, 1.49 0.71
‡3 yr 1.56 1.04, 2.32 0.03
Duration of diabetes
at kidney transplant (yr)
0.98 0.96, 0.999 0.04
Age at pancreas
transplantation (yr)
0.96 0.95, 0.98 <0.001
eGFR at pancreas
transplantation (mL/min)
0.99 0.98, 0.995 0.003
Kidney donor age (yr) 1.01 1.003, 1.03 0.011
Kidney donor type <0.001
Living Ref. Ref. Ref.
SCD 1.07 0.77, 1.49 0.70
ECD or DCD 2.38 1.63, 3.48 <0.001
Induction at kidney
transplant
0.07
None Ref. Ref. Ref.
ATG/thymoglobulin 1.12 0.83, 1.53 0.46
Anti-IL 2 receptor
antibodies
0.90 0.61, 1.33 0.60
Alemtuzumab 3.11 1.24, 7.76 0.02
Model 2b Months between
transplantations
All 1.01 1.004, 1.014 <0.001
<1 yr 1.01 0.94, 1.08 0.89
1 to <3 yr 1.02 0.98, 1.05 0.44
‡3 yr 1.01 1.001, 1.02 0.03
SCD, standard criteria donor; ECD, expanded criteria donor; DCD, donor after
cardiac death; eGFR, estimated glomerular filtration rate; ATG, anti-thymocyte
globulin.
aTime interval as categorical variable.
bTime intervals as continuous variable.
Table 3. Clinical correlates of death following pancreas transplantation
Variables Hazard ratio 95% CI p
Model 1a Years between
transplantations
0.24
<1 yr Ref. Ref. Ref.
1 to <3 yr 1.22 0.92, 1.61 0.17
‡3 yr 1.30 0.93, 1.81 0.13
Age at pancreas
transplantation (yr)
1.03 1.01, 1.06 0.002
Recipient BMI at
pancreas transplantation
(kg/m2)
0.95 0.93, 0.98 0.001
eGFR at pancreas
transplantation (mL/min)
0.99 0.98, 0.994 <0.001
History of peripheral
vascular disease, yes
1.58 1.17, 2.79 0.003
History of coronary
artery disease, yes
1.51 1.16, 1.97 0.002
African American
kidney donor, yes
1.95 1.29, 2.94 0.001
Dialysis history, yes 1.74 1.30, 2.33 0.001
Induction at pancreas
transplantation
<0.001
None Ref. Ref. Ref.
ATG/thymoglobulin 0.78 0.60, 1.00 0.06
Anti-IL 2 receptor
antibodies
0.54 0.38, 0.76 0.001
Alemtuzumab 0.49 0.26, 0.92 0.03
Model 2b Months between
transplantations
1.002 0.998, 1.006 0.37
BMI, body mass index; eGFR, estimated glomerular filtration rate; ATG, anti-
thymocyte globulin.
aTime interval as a categorical variable.
bTime intervals as continuous variable.
Table 4. Renal function at pancreas transplant and clinical outcome
Renal functiona (mean ± SD, mL/min) Adjusted HR 95% CI p
Kidney graft failure
eGFR ‡65 (79.5 ± 15.4) Ref. Ref. Ref.
eGFR 50 to <65 (56.9 ± 4.4) 1.27 0.89, 1.82 0.19
eGFR <50 (42.9 ± 5.0) 1.93 1.35, 2.77 <0.001
Death
eGFR ‡65 (79.5 ± 15.4) Ref. Ref. Ref.
eGFR 50 to <65 (56.9 ± 4.4) 1.51 1.13, 2.02 0.005
eGFR <50 (42.9 ± 5.0) 1.95 1.46, 2.62 <0.001
aAbbreviated Modification of Diet in Renal Disease formula.
eGFR, estimated glomerular filtration rate.
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pancreas transplantation affected subsequent
uncensored kidney graft loss but the impact on
death-censored graft survival and patient survival
was not separately addressed and the direction of
such effect was not clear from their analyses (8).
Thus, our study provides additional information
that may be helpful in the assessment of the benefit
and risk when PAK transplantation is considered.
The importance of renal function prior to PAK
transplantation on the subsequent kidney graft
survival has been recognized by several investiga-
tors (1, 8, 18). Our study is in full agreement with
these previous observations, and in addition, we
demonstrated that the levels of kidney function at
the time of PAK transplantation, independent of
time interval between kidney and pancreas trans-
plantation, impact the risk of death, which is
consistent with similar observation among kidney
transplant patients (19). Although we did not
identify a threshold of renal function levels below
which PAK transplantation should not be recom-
mended, an appropriate counseling for patients
seeking a PAK transplant with emphasis on the
degree of renal function should be provided.
Our study has several major limitations. First, as
this is a retrospective national registry data anal-
ysis, the bias in patient selection for pancreas
transplantation and post-transplant care by indi-
vidual transplant centers could not be accounted
for. For the same reason, the conclusion relies
heavily on the accuracy of data collection from
individual transplant centers reported to OPTN/
SRTR. Second, separation of patients into three
groups was somewhat arbitrary and without a
particular rationale; thus, as a consequence, the
patients from the three groups were dissimilar on
many aspects. In particular, patients from Group 3
were more likely to have their kidney transplant
from an early era (prior to 1995) and had more
frequent use of cyclosporine as the initial CNI and
less use of mycophenolates as an anti-proliferative
agent. Although we adjusted for these and other
variables in our multivariate analyses, this adjust-
ment may have not eliminated the impact stemmed
from the difference in care and in immunosuppres-
sive regimens over the years. Third, the lack of
detailed and important clinical information regard-
ing clinical events such as the occurrence of biopsy
proven rejection, CNI nephrotoxicity and infec-
tion, the degree of glycemia control and the
presence of proteinuria prior to pancreas trans-
plantation, etc., prevents us from pinpointing the
specific mechanisms of our findings. Finally, our
observations do not address the question whether
having a pancreas transplant is better than not
having it when the waiting time for a pancreas
transplant is long and renal function is suboptimal.
Thus, the time interval need not be used as a sole
criteria to determine whether a qualified type 1
diabetic kidney transplant patient should receive a
pancreas transplant or not. Rather, it should be
considered in conjunction with many other factors
such as the stability of kidney transplant and the
degree of renal function as our study shows that
better renal function was associated with good
clinical outcome following pancreas transplanta-
tion.
In conclusion, longer time interval beyond
three yr following kidney transplantation and re-
duced renal function were independently associated
with an increased risk of kidney graft loss in PAK
transplant recipients. Thus, reducing the waiting
time for qualified type 1 diabetic kidney transplant
patients and optimizing their renal function prior to
pancreas transplantation should be emphasized.
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